Nathan L. Mata
And share age, we Tom. adolescent you, patients are aged in of a adolescents What XX it like oral took attending. Phase to analyses you, that and trial disease. from Stargardt Thank XX X-year II in have enrolled we'd open-label X today years to you new XX thank Stargardt subjects with was milligrams our for study Tinlarebant This everyone, some study which daily.
want of analysis the our all you study. first been The has previously genetic of I not to analysis patients a in show This reported. is
X an You'll see ABCAX mutation. for there for there's allele are entries. each each because subject, That's
see of And ABCAX an of is at gene. the the XX so we're looking them. Rando Dr. XX biallelic Stargardt gene, This of mutations. identifier XX XX conducted subjects -- X have way, who you can severe Allikmets, by And of by was the analysis,
are deleterious. Depletion and called the severe X, scores with There are of And have their ABCAX X the to above XX. subjects, the scores cohort through mutations. are on very It's here is who So prominently affected mutations. is X point subjects moderate to the a way X, these subjects, classified note that the very, genes is our only of with important on you In predicted among analysis, score have Annotated most well XX see, and above Combined X our be Dependent X% alleles the a subject of can all score. those this exception allele
affected So this severely is a very cohort.
them, lesions only because baseline. XX, came you important is that, autofluorescent atrophic lesion. never XX subjects in is subjects, next an X, show of this analysis particular spawned to these and X, at like with I'd of study, The X, in X subjects This
rate overall atrophic monitoring of measure a previously So then we transition the reported rate remarkably the the lesion And And autofluorescent of lesion lesion. the growth we reduced lesion growth in we to that were have the atrophic type. the formed, population. once
grow over not Now atrophic XX very we're mutations. they showing had months, lesion an you severe subjects did in that those
So benign mutations. or could not subjects mild in attributed to the these absence be lesion of growth
important one XX mutation. a are are shows X allelic siblings. is They us that and exact analysis next because brothers. The X it very the X subjects Subjects have same
I You they across brother/sister. XX have have The mutations have alleles. mutations. some same other information the very genetic identical because now. mutations reason identical is right Phase right seeing I'll what in are II there, predict now you that exact And can you see study, XX, this that is the course. we're important same the of also disease that can not subjects it's and suggested tell They investigators show
loss before we came did acuity analysis they disease eye, all loss, mean time a is time found severe each looked we were that of had time XX period loss they in and is vision bilateral the and between study, the the diagnosed study. all there visual the of have over letters they that came they different is of of subjects per at we letters the have the vision into annual we XX into What per were vision And what eye, eye. who subjects Here, duration. had subjects very before a loss bilateral X
not well, That's lesions reasons. that atrophic One, X tells it in us the visual lesions fact, loss. fovea yet. these subjects in autofluorescent Remember, for significant acuity grown cause have do, because,
is has duration, the can look whereas Yet brother the brother, significant X, not. XX, did duration disease acuity again, you They his have disease for XX, but if that's whereas XX XX letters, you the subjects sibling the not. only X-year X Subjects visual different. thing again, important lost whereas vision, thing sister their lost XX Same similar other and XX brothers. subjects X with see X-year XX very Subject disease years. sister X, loss did X are XX. of The subject and and and an only the at subject duration, has is
visual us, So genetic identical pertains that loss. so in do it tell necessarily mutations acuity predict as disease these identical as not data fact, progression far to
subjects, subjects right. months, I say only visual loss all of acuity first letters side then to the XX That all of whole letters. XX shown over subjects lost period those a was left-hand the mean X analysis of the that the XX in mean an only is on on over want of all This X subjects months. is months, the X over and
So that's per letters year. X.X roughly
the letters, per that focus if just losing came they've Now X XX roughly in only year, is over on year. months, subjects see X.X XX we letters X now about lost per about we letters which
to So X year is per acuity a we've preservation year. taken these loss significant in of XX-letter down the substantial letters subjects. That visual per
autofluorescent data a is visual you atrophic to upper actual important side. right-hand the shown convert graphic And of it's analysis. The growth on XX. is This lesion next to lesions. on subject like analysis that lesion to And from the show that I'd the these growth note the is lesions
within see lesions Over autofluorescent very large spawned there's autofluorescent will can be which as time, at decreased lesions autofluorescent referred You autofluorescent decreased lesions. is or lesion, QDAF. as The atrophic baseline, are lesions. referred this to autofluorescence, the questionably definitely to
So left the graphic lesion of here, if type, is there's the lesion atrophic the shown at and looking lower -- decrease the autofluorescent size. between the of lesion the to and autofluorescence a And atrophic the of increase transition that right-hand the we're side. proportionality lower on we're seeing
month autofluorescent We're that subject atrophic did grew follow between XX%, of grow the XX. area XX analysis subject before, lost subjects, lesions, that lesion. As of but a I was and grow lesion decrease within that you the the nowhere to those the zone, very X certainly atrophic an But at of see because subjects area, lesion never can does including not clear X said showing in the correlation the increase else. autofluorescent atrophic atrophic in the
the we history. lower know than So from in natural that within growth have analysis growth is prior we lesion to this And confined zone. significantly lesion
error which only be atrophic And to now. get of believe lesion subject an X, autofluorescence that subject, There's of to identified initially due the image software, right outside could one I'll we that grew area. reading
We human -- the typically software retinal ophthalmologists software problem This finding it a most a the in people with use imaging by error. The is this grade and is accompanies software lesions region that is affected back the camera of to lesions. that software. that allows the eye called Heidelberg use
atrophy. demarcate of look humans lesions So have zone the and to at actually the
And sometimes, readers don't agree.
where you difference to you it arbitrator. have go a case a has of to can opinion and an have So
be time-consuming today. being this and So a what is very error-prone used can is process, but this
a developed has center lesions which rely on algorithm reading for not does bias. reader new Our reading subjective
which reader before, to most the mathematical the about optic when it's loss. And just at is macular of acuity disc In classification lesion that a lesions well fact, of it And uses retinal as and the focuses you're it on look proximity of the X-millimeter bias. tissue. talking density as I healthy said on area, the visual the as of to independent based important
reader So really is reporting the it's provided. computer lesion pixel the at whatever just and algorithm area. the software doing getting across is back data And looking the densities from the all
shows I algorithm, at have grading in you can lesion macular there's to And So left-hand lesion subjects you particular involvement lesion And find solid growth. the look was you within the macular What the of so from a show XX data third we software. of lines line these side, the this eyes of image see using using if the we a the did, lesion area new And line. want the the in that the patients fitted you that the our baseline. you polynomial growth we data show time. see found, on dots monitor macular fact, trend data that fact, this reanalysis of through X dotted can over grading that and border actual we
see You very out no But about from by was of month the within grow XX. indicate lesion. month zone. macular would growth side, the are you there XXX% the to all on millimeters the starting that zone of clear. absolutely XX, from to that do that XX atrophy. can can The of atrophy The baseline right-hand see percentage further month occupied then involvement it's X-millimeter And lesions X
no subjects As months. here, to of more from you atrophic showing a encroachment lesion and our the XX than into it's macula, static X% can see XX are the
we're this you is it So report the I showed to earlier. consistent stabilization and with acuity data, visual that pleased of very
in and Geographic the an a are duration, same have Finally, similar. There's looking that design note and we're III study events. efficacy They of lesion III Atrophy. same Phase very I atrophic growth looking interim to Stargardt X the at They Phase safety same disease very, It's the Stargardt III And in want our all X:X judge course, important at to we're have same randomization. the to adverse years, analysis. and bit the that with dose. design assessments trial talk trial same the about Phase in the little
X only these differences in There's studies.
study to GA of a indication, the higher the with enrollment First, population. higher for and GA prevalence reflect the Stargardt; secondly, in then instead the disease predicted population the of
with to to I'll turn you. over Thank that, So it Hao-Yuan discuss financials.
